Skip to main content
OpenTrials
Completed

NCT Number: NCT02421055

Longitudinal Phenotyping of Bariatric Surgery Patients

Recent studies have shown that bacteria within the gut play an important role in diabetes improvement after bariatric (weight-loss) surgery. Bariatric surgery fundamentally changes the environment within the gut, which results in changes to the makeup of the trillions of bacteria living within it. These changes in the gut bacteria can affect the body in a number of complex ways, which we are only just beginning to understand. For example, gut bacteria breakdown food we are unable to absorb ourselves, leading to altered sugar levels and can release molecules that act to reduce appetite.

In this study we aim to find out how bariatric surgery changes the gut bacteria and how this leads to weight loss and improvement of diabetes. With this understanding we hope to discover potential targets for future treatments, such as identifying beneficial bacteria that could be supplemented with probiotics in patients.

Additionally, although highly successful, up to 30% of obese patients do not undergo improvement of their diabetes after bariatric surgery. We aim to identify molecules within the patient's blood or urine that are able to predict the likely chance a patient will undergo improvement in their diabetes after bariatric surgery to help clinicians select patients most likely to benefit.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study aims to assess how the gut microbiome affects the host phenotype following bariatric surgery through altered gut microbiome-host co-metabolism. The secondary objective is to identify novel biomarkers for the preoperative prognostication of T2DM remission following bariatric surgery.

The study will longitudinally phenotype obese diabetics and non-diabetics undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy surgery. Patients will be assessed preoperatively and at 3 months and 1 year postoperatively. Clinical measures recorded will include; 1) anthropometric & physiological measurements, 2) demographic details, 3) biochemical parameters including HbA1c, 4) anti-hyperglycaemic and other medication use, 5) co-morbidity status and 6) dietary choices through 24hr dietary recall questionnaires.

Blood, urine and stool samples will be collected at the above time points. Changes to the microbiome will be assessed using metagenomic sequencing. Global metabonomic profiles of serum, urine and faecal water will be generated using 1H-NMR. Further targeted analyses of bile acid and short-chain fatty acid profiles will be performed using LC-MS / GC-MS.

The study will utilise multivariate statistical analysis techniques to identify metabolic pathways altered following intervention, and novel host-microbiome co-metabolism pathways that impact upon phenotype. A supervised multivariate analysis, mapping T2DM outcomes to metagenomic and metabonomic data will be performed with the aim of identifying novel preoperative biomarkers that are able to prognosticate T2DM resolution following bariatric surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obese (BMI>30kg/m2)
  • Type 2 Diabetes Mellitus and non-diabetic
  • Failure of efforts at lifestyle modification and dieting
  • Fitness for anaesthesia and procedure
  • Willingness to comply with the trial protocol

Exclusion criteria

  • Previous bariatric surgery
  • Pregnancy or intention to become pregnant during trial period
  • Lack of capacity to consent
  • Previous major abdominal surgery (Small or large bowel resection, stomach, liver, pancreatic or splenic surgery. Does not include patients who have previously had an appendicectomy, cholecystectomy or hernia repair).

Treatment and study plan

Laparoscopic Roux-en-Y Gastric Bypass

Procedure

Laparoscopic sleeve gastrectomy

Procedure

Primary outcomes

  1. Number of Participants With Complete Diabetes Remission at 3 Months

    Time frame: 3 months

    Participants with HbA1c <6% (42mmol/mol), off anti-diabetic medication, at 3 months

Secondary outcomes

  1. Partial Diabetes Remission

    Time frame: 3 months

    HbA1c <6.5% (48mmol/mol), off anti-diabetic medication, at 3 months. (Includes participants with complete remission).

  2. HbA1c Improvement

    Time frame: 3 months

    Reduction in HbA1c at 3 months

  3. Weight Loss

    Time frame: 3 months

    Weight loss at 3 months

  4. BMI Reduction

    Time frame: 3 months

    BMI reduction at 3 months

  5. Complete Diabetes Remission

    Time frame: 1 year

    HbA1c <6% (42mmol/mol), off anti-diabetic medication, at 1 year

  6. Partial Diabetes Remission

    Time frame: 1 year

    HbA1c <6.5% (48mmol/mol), off anti-diabetic medication, at 1 year. (Includes participants with complete diabetes remission).

  7. HbA1c Improvement

    Time frame: 1 year

    Reduction in HbA1c at 1 year

  8. Weight Loss

    Time frame: 1 year

    Weight loss at 1 year

  9. BMI Reduction

    Time frame: 1 year

    BMI reduction at 1 year

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Registry information

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Apr 20, 2015
Registry last updated
Nov 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.